SWISS TUMOR BOARD Lung Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne...

11
SWISS TUMOR BOARD Lung Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne

Transcript of SWISS TUMOR BOARD Lung Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne...

Page 1: SWISS TUMOR BOARD Lung Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne.

SWISS TUMOR BOARDLung Cancer

March 26, 2009Novotel Bern

Prof. Dr. Mahmut Ozsahin

Lausanne University Medical Center (CHUV), Lausanne

Page 2: SWISS TUMOR BOARD Lung Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne.

Case #1N. Mach

• Male patient, 79-yr-old

• Left lower lobe tumor (2.2 cm)

• PET: single + lesion (SUV 8) LLL

• Bronchoscopy (–)

• Percutaneous transthoracic bx: not done

• Diagnosis: cT1N0M0 lung cancer (stage I vs. infection (less unlikely)

• Decision: Observation**Patient refused surgery and radiotherapy

Page 3: SWISS TUMOR BOARD Lung Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne.

Case #1N. Mach

• Surgery is the standard treatment for stage I/II NSCLC

• If surgery not possible, localized RT

• Bad pulmonary function stereotactic extracranial RT (or Tomotherapy®, Cyberknife®, Novalis®) would be proposed (even without histological confirmation)

• No prospective comparison (medically inoperable patients)

Page 4: SWISS TUMOR BOARD Lung Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne.

Early operable NSCLC (stage IA, IB)

Surgery alone evidence level B

To have clear margins level A

Operation by trained surgeon level A

RT or re-excision for R1, R2 level B

Neo- or adjuvant RT for R0 level D

Adjuvant chemotherapy (stage IB) level B

Neoadjuvant chemotherapy level I

Smythe, Chest 2003

American College of Chest Physicians

Page 5: SWISS TUMOR BOARD Lung Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne.

RT is treatment of choice in medically inoperable or refusing patients (evidence level B).

5-yr. OS = 30% (meta-analysis)

No randomized comparison between RT vs. supportive care

Rowell, Thorax 2001

Early inoperable NSCLC (stage IA, IB)

Page 6: SWISS TUMOR BOARD Lung Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne.

Tomotherapy

Stereotactic RT

Page 7: SWISS TUMOR BOARD Lung Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne.

1x 30 Gy

3 months 6 months

Cybeknife

Page 8: SWISS TUMOR BOARD Lung Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne.

3x20 Gy

Page 9: SWISS TUMOR BOARD Lung Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne.
Page 10: SWISS TUMOR BOARD Lung Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne.

Case #1N. Mach

• Progression 9 months later

• NSCLC, non squamous; 5-cm mass LLL, no lymph node metastases

• Left pneumonectomy, pT2N1M0, re-stage IIB

• If R0, no indication for postoperative RT

• However, adjuvant chemotherapy is indicated (depending on medical conditions): IALT, European Big Lung, ALPI, ANITA, and meta-analysis (Pignon et al, J Clin Oncol 2008)

Page 11: SWISS TUMOR BOARD Lung Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne.

Surgery alone evidence level B

To have clear margins level A

Operation by trained surgeon level A

Postop RT for R1, R2 or pN2 level C

Adjuvant chemotherapy level A

Adjuvant RT for R0 level D

Neoadjuvant chemo + RT level D

Scott, Chest 2003

American College of Chest Physicians

Intermediate stage II NSCLC